Top Ten most popular articles on Pharmafile.com this week!

Published on 23/11/18 at 12:16pm

The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the top spot this week. Meanwhile MHRA chief Dr Ian Hudson announced he was stepping down.

Equally as Brexit inched ever closer it was revealed that use of antidepressant had gone up in the month following the referendum. At the same time, the ABPI responded to Theresa May’s new deal.

In the wake of the midterms in the United States, American firm Pfizer asked Senator Cindy Hyde-Smith to refund campaign donations after the Republican joked about ‘public hanging’ in her home state of Mississippi.

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) for patients under the age of 25 via the Cancer Drugs Fund.

AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent Phase 3 trial in the treatment of previously untreated patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

American pharma firm Pfizer have lost in the final round of a protracted court battle over the patent on epilepsy drug Lyrica, after Britain’s highest court ruled against the company, in a case surrounding the $5 billion a year drug.

The Medicines and Healthcare products Regulatory Agency (MHRA), the regulator responsible for the efficacy and safety of medicines in the UK, has announced that its Chief Executive is to step down from the role in September next year.

Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who have at least four days affected by the condition per month, it has emerged.

The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin (bevacizumab) as a first-line treatment for renal cell carcinoma (RCC) due to insufficient data.

Mission Statement

Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,

Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches